What is the risk of regional node metastasis in a 0.70 mm thick melanoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 19, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Risk of Regional Node Metastasis in 0.70 mm Thick Melanoma

The risk of regional node metastasis in a 0.70 mm thick melanoma is less than 5%.

Evidence-Based Assessment

According to the American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) clinical practice guideline, melanomas with Breslow thickness ≥0.75 mm have a sentinel lymph node (SLN) positivity likelihood of 8.8% (95% CI, 6.4% to 11.2%) 1. Since the melanoma in question is 0.70 mm thick, which falls below this threshold, the risk would be even lower.

The National Comprehensive Cancer Network (NCCN) guidelines specifically address this issue, stating that "in general, SLNB is not recommended for primary melanomas ≤0.75 mm thick, unless there is significant uncertainty about the adequacy of microstaging" 1. This recommendation is based on the low probability of finding positive sentinel nodes in such thin melanomas.

Risk Stratification for Thin Melanomas

For melanomas ≤0.75 mm thick, the risk factors that might increase the likelihood of sentinel node positivity include:

  • Ulceration
  • High mitotic rate
  • Lymphovascular invasion
  • Clark level ≥ IV

However, the NCCN guidelines note that these conventional risk factors "are very uncommon in melanomas ≤0.75 mm thick" 1. When these factors are absent in a 0.70 mm melanoma, the risk of regional node metastasis remains well below 5%.

Clinical Decision-Making

The 2018 ASCO/SSO guidelines report that a systematic review of 60 studies found that after adjusting for all potential risk factors, melanomas with Breslow thickness <0.75 mm have a significantly lower risk of SLN positivity compared to those ≥0.75 mm 1.

The NCCN guidelines from 2013 specifically state that "SLNB is not recommended for primary melanomas ≤0.75 mm thick" 1, which has been consistently maintained in later versions of the guidelines 1.

Practical Implications

For a 0.70 mm thick melanoma:

  1. Sentinel lymph node biopsy is generally not recommended due to the low yield
  2. The risk of regional node metastasis is less than 5%
  3. Wide local excision with appropriate margins is the standard treatment
  4. Regular follow-up is important for monitoring

Common Pitfalls to Avoid

  1. Overestimating risk: Don't assume that all melanomas carry a significant risk of nodal metastasis. Thin melanomas (<0.75 mm) without adverse features have an excellent prognosis.

  2. Unnecessary procedures: Performing SLNB on all patients with thin melanomas leads to unnecessary procedures with potential complications for very little benefit.

  3. Neglecting other risk factors: While thickness is the primary determinant, in rare cases where ulceration or high mitotic rate is present in a thin melanoma, the risk may be slightly higher.

In conclusion, based on the most recent and highest quality evidence, the risk of regional node metastasis in a 0.70 mm thick melanoma is less than 5% (option A).

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.